107 related articles for article (PubMed ID: 23563734)
1. Interleukin-4 receptor α-based hybrid peptide effectively induces antitumor activity in head and neck squamous cell carcinoma.
Seto K; Shoda J; Horibe T; Warabi E; Ishige K; Yamagata K; Kohno M; Yanagawa T; Bukawa H; Kawakami K
Oncol Rep; 2013 Jun; 29(6):2147-53. PubMed ID: 23563734
[TBL] [Abstract][Full Text] [Related]
2. Targeting interleukin-4 receptor α with hybrid peptide for effective cancer therapy.
Yang L; Horibe T; Kohno M; Haramoto M; Ohara K; Puri RK; Kawakami K
Mol Cancer Ther; 2012 Jan; 11(1):235-43. PubMed ID: 22084165
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma.
Gyanchandani R; Sano D; Ortega Alves MV; Klein JD; Knapick BA; Oh S; Myers JN; Kim S
Oral Oncol; 2013 Aug; 49(8):761-70. PubMed ID: 23623402
[TBL] [Abstract][Full Text] [Related]
4. Effect of interleukin (IL)-4 cytotoxin on breast tumor growth after in vivo gene transfer of IL-4 receptor alpha chain.
Kawakami K; Kawakami M; Husain SR; Puri RK
Clin Cancer Res; 2003 May; 9(5):1826-36. PubMed ID: 12738741
[TBL] [Abstract][Full Text] [Related]
5. Effect of docetaxel on the surgical tumor microenvironment of head and neck cancer in murine models.
Yoo GH; Subramanian G; Piechocki MP; Ensley JF; Kucuk O; Tulunay OE; Lonardo F; Kim H; Won J; Stevens T; Lin HS
Arch Otolaryngol Head Neck Surg; 2008 Jul; 134(7):735-42. PubMed ID: 18645124
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 4 receptor-directed cytotoxin therapy for human head and neck squamous cell carcinoma in animal models.
Strome SE; Kawakami K; Alejandro D; Voss S; Kasperbauer JL; Salomao D; Chen L; Maki RA; Puri RK
Clin Cancer Res; 2002 Jan; 8(1):281-6. PubMed ID: 11801570
[TBL] [Abstract][Full Text] [Related]
7. Expression of interleukin-4 receptor alpha in human pleural mesothelioma is associated with poor survival and promotion of tumor inflammation.
Burt BM; Bader A; Winter D; Rodig SJ; Bueno R; Sugarbaker DJ
Clin Cancer Res; 2012 Mar; 18(6):1568-77. PubMed ID: 22261806
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-28B acts synergistically with cisplatin to suppress the growth of head and neck squamous cell carcinoma.
Yoshimoto K; Kishida T; Nakano H; Matsui M; Shin-Ya M; Shimada T; Nakai S; Imanishi J; Takeuchi M; Hisa Y; Mazda O
J Immunother; 2011 Mar; 34(2):139-48. PubMed ID: 21304406
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-13 receptor alpha2 chain in human head and neck cancer serves as a unique diagnostic marker.
Kawakami M; Kawakami K; Kasperbauer JL; Hinkley LL; Tsukuda M; Strome SE; Puri RK
Clin Cancer Res; 2003 Dec; 9(17):6381-8. PubMed ID: 14695138
[TBL] [Abstract][Full Text] [Related]
10. A novel interleukin-13 receptor alpha 2-targeted hybrid peptide for effective glioblastoma therapy.
Kurihara R; Horibe T; Shimizu E; Torisawa A; Gaowa A; Kohno M; Kawakami K
Chem Biol Drug Des; 2019 Jul; 94(1):1402-1413. PubMed ID: 30903640
[TBL] [Abstract][Full Text] [Related]
11. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC
Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070
[TBL] [Abstract][Full Text] [Related]
12. Indications for an alternative effective treatment of head and neck squamous cell carcinoma with temsirolimus plus bevacizumab: from bench to bedside?
Trafalis DT; Alifieris C; Dalezis P; Geromichalos G; Sitaras NM
Anticancer Drugs; 2012 Sep; 23(8):874-82. PubMed ID: 22510794
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).
Patel V; Lahusen T; Leethanakul C; Igishi T; Kremer M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS; Senderowicz AM
Clin Cancer Res; 2002 Nov; 8(11):3549-60. PubMed ID: 12429646
[TBL] [Abstract][Full Text] [Related]
14. Endostatin inhibits migration and invasion of head and neck squamous cell carcinoma cells.
Wilson RF; Morse MA; Pei P; Renner RJ; Schuller DE; Robertson FM; Mallery SR
Anticancer Res; 2003; 23(2B):1289-95. PubMed ID: 12820385
[TBL] [Abstract][Full Text] [Related]
15. Combined molecular targeted drug therapy for EGFR and HER-2 in head and neck squamous cell carcinoma cell lines.
Kondo N; Tsukuda M; Sakakibara A; Takahashi H; Hyakusoku H; Komatsu M; Niho T; Nakazaki K; Toth G
Int J Oncol; 2012 Jun; 40(6):1805-12. PubMed ID: 22344385
[TBL] [Abstract][Full Text] [Related]
16. A single replacement of histidine to arginine in EGFR-lytic hybrid peptide demonstrates the improved anticancer activity.
Tada N; Horibe T; Haramoto M; Ohara K; Kohno M; Kawakami K
Biochem Biophys Res Commun; 2011 Apr; 407(2):383-8. PubMed ID: 21396910
[TBL] [Abstract][Full Text] [Related]
17. Identification, characterization, and targeting of IL-4 receptor by IL-4-Pseudomonas exotoxin in mouse models of anaplastic thyroid cancer.
Joshi BH; Suzuki A; Fujisawa T; Leland P; Varrichio F; Lababidi S; Lloyd R; Kasperbauer J; Puri RK
Discov Med; 2015 Nov; 20(111):273-84. PubMed ID: 26645899
[TBL] [Abstract][Full Text] [Related]
18. Local delivery system of cytotoxic agents to tumors by focused sonoporation.
Iwanaga K; Tominaga K; Yamamoto K; Habu M; Maeda H; Akifusa S; Tsujisawa T; Okinaga T; Fukuda J; Nishihara T
Cancer Gene Ther; 2007 Apr; 14(4):354-63. PubMed ID: 17273182
[TBL] [Abstract][Full Text] [Related]
19. CRKL plays a pivotal role in tumorigenesis of head and neck squamous cell carcinoma through the regulation of cell adhesion.
Yanagi H; Wang L; Nishihara H; Kimura T; Tanino M; Yanagi T; Fukuda S; Tanaka S
Biochem Biophys Res Commun; 2012 Feb; 418(1):104-9. PubMed ID: 22244889
[TBL] [Abstract][Full Text] [Related]
20. Intraoperative therapy with liposomal drug delivery: retention and distribution in human head and neck squamous cell carcinoma xenograft model.
Wang SX; Bao A; Phillips WT; Goins B; Herrera SJ; Santoyo C; Miller FR; Otto RA
Int J Pharm; 2009 May; 373(1-2):156-64. PubMed ID: 19429301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
